Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of included patients

From: In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo

  ASAQ (n = 144) AL (n = 144) p value
Age, in months 32.2 (20.0–47.0) 30.9 (21.0–41.5) 0.412
# Male (%) 65 (79) 65 (79) 1.000
Weight for height Z-score −0.59 (−1.39 to 0.22) −0.68 (−1.40–0.08) 0.484
Temperature in  °C 38.8 (38.0–39.7) 39.02 (38.4–39.8) 0.049
Parasite density/µl at day 0 63,637 (15, 211–95, 962) 45,154 (14, 225–94, 746) 0.826
Log parasite density at day 0 10.5 (9.6–11.5) 10.4 (9.6–11.5) 0.935
Haemoglobin in g/dl at day 0 9.5 (8.5–10.8) 9.7 (8.7–10.8) 0.316
  1. All data is presented as the mean with the interquartile range (IQR) in brackets, unless otherwise stated